BIOMAT Database Logo BIOMAT Database Logo

Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. 2022

Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.

This study aimed to evaluate the existing staging systems for multiple myeloma (MM) in the real world. From January 2010 to June 2019, we retrospectively analyzed 859 newly diagnosed MM patients from two institutions. Clinical data including laboratory findings, imaging examinations and staging system were obtained by reviewing medical records. Survival distributions were estimated using the Kaplan-Meier curve analysis, and Cox proportional hazards model were used to identified risk factors. The overall survival (OS) of eligible patients was 61.0 months. The Revised International Staging System (R-ISS) had a larger receiver operating characteristic curve area (0.603) than both the International Staging System (0.573) and the Durie Salmon staging system (0.567). In the group receiving immunomodulatory agents-based regimens, the median OS was 92.0 months in R-ISS I, 63.0 months in R-ISS II and 18.0 months in R-ISS III (p < 0.0001). In the group receiving proteasome inhibitors-based regimens, the median OS was 102.0 months in R-ISS I, 63.0 months in R-ISS II and 22.0 months in R-ISS III (p < 0.0001). In different subgroups grouped according to age, hemoglobin (HGB), creatinine, and Ca, R-ISS also had a good stratification effect. Patients in R-ISS II, which accounted for 69.9% of all patients, were further analyzed. Univariate and multivariate Cox analyses revealed that age >65 years (p = 0.001), HGB < 100 g/L (p < 0.001), elevated LDH (p = 0.001), and Ca (p = 0.010) were independent predictors of worse prognosis within R-ISS II. To conclusion, R-ISS remains a valuable staging system in the real world of the novel drug era. However, patients classified as R-ISS II still have great heterogeneity.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D061988 Proteasome Inhibitors Compounds that inhibit the function or proteolytic action of the PROTEASOME. Proteasome Endopeptidase Complex Inhibitors,Proteasome Inhibitor,Inhibitor, Proteasome,Inhibitors, Proteasome

Related Publications

Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Prognostic factors for multiple myeloma in the era of novel agents.
September 2008, Annals of oncology : official journal of the European Society for Medical Oncology,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Multiple myeloma in the era of novel agents.
April 2009, Seminars in hematology,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Prognostic factors and staging systems of multiple myeloma:.
October 2007, Chinese medical journal,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Prognostic significance of stratification systems in multiple myeloma. II. Clinical staging systems.
January 1985, Neoplasma,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Extramedullary disease in multiple myeloma in the era of novel agents.
June 2015, British journal of haematology,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Maintenance therapy for multiple myeloma in the era of novel agents.
January 2015, Hematology. American Society of Hematology. Education Program,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Prognostic factors for multiple myeloma in the era of novel therapies.
November 2018, Expert review of hematology,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.
February 2021, International journal of hematology,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
[Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
January 1990, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna,
Yufeng Shang, and Yanxia Jin, and Hailing Liu, and Lu Ding, and Xiqin Tong, and Honglei Tu, and Longkai Zang, and Chenyao Lin, and Jinsong Hu, and Fuling Zhou
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
August 2010, European journal of haematology,
Copied contents to your clipboard!